Personal Injury Law

Generic Drug Makers Under Fire From F.D.A.

By Edward Bills

The F.D.A. this week posted a letter on its Web site to Canadian generic drug maker Apotex that cited various manufacturing violations among its drugs and the failure to notify regulators. The warning letter was issued “because of serious and repeat violations from the 2008 and 2009 inspections,” F.D.A. officials wrote. The warning comes at the same time another generic drug maker, Ranbaxy, has come under fire from the F.D.A. for problems at three of its manufacturing plants, one in New York. The F.D.A. held a public advisory meeting this week to discuss the whether additional regulation of the drugs would increase public confidence in the products, the New York Times reports.

Full post as published by Bodily Injury Blog on April 16, 2010 (boomark / email).